Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 4:02 PM ET

Healthcare Equipment and Supplies

Company Overview of Bayer HealthCare LLC

Company Overview

Bayer HealthCare LLC develops, manufactures, and markets healthcare and medical products. The company offers blood glucose monitoring systems, diabetes self-care software, and lancing devices; and YAZ, a low-dose oral contraceptive. It also provides diagnostic testing for urinalysis, DCA, immunology, blood gas, and hematology; molecular and clinical chemistry testing to assess and manage health in a myriad of disease states, including cardiovascular, kidney and infectious diseases, oncology, and virology; and Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms, including nausea, phonophobia, and photophobia. The company offers an...

100 Bayer Boulevard

PO Box 915

Whippany, NJ 07981-0915

United States

Founded in 2002





Key Executives for Bayer HealthCare LLC

President and General Manager of Animal Health Division
President and General Manager, Animal Health Division, North America
President of Consumer Care Division
Sr. Vice President, Global Head, Product Supply -Biotech and Site Head
Bayer HealthCare Representative U.S.A.
Compensation as of Fiscal Year 2015.

Bayer HealthCare LLC Key Developments

Bayer Receives FDA Approval for BETACONNECT - Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment

Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) approved BETACONNECT, the first and only electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). BETACONNECT will be available exclusively to BETASERON (interferon beta-1b) patients beginning in early 2016. BETASERON is a prescription medicine used to reduce the number of relapses in people with relapsing forms of multiple sclerosis. This includes people who have had their first symptoms of multiple sclerosis and have an MRI consistent with multiple sclerosis. BETASERON will not cure MS but may decrease the number of flare-ups of the disease. After completing the preparation of BETASERON, patients may administer BETASERON by using the BETACONNECT, which should only be used with the syringes provided in the BETASERON packaging.

U.S. Food & Drug Administration Approves Bayer HealthCare's Finacea(R) (azelaic acid) Foam 15% for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea

Bayer HealthCare announced that the U.S. Food & Drug Administration (FDA) has approved Finacea® (azelaic acid) Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Papulopustular rosacea is a skin disease causing inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead. Finacea® Foam was developed as part of a research and development collaboration between Foamix Pharmaceuticals Ltd. and Bayer HealthCare, utilizing Foamix's proprietary foam technology platform. According to a license agreement between the two companies, Foamix is entitled to royalties and certain milestone payments upon commercialization of Finacea® Foam.

Bayer HealthCare and Johns Hopkins University Collaborate to Develop New Ophthalmic Therapies

Bayer HealthCare and The Johns Hopkins University in Baltimore have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The partners will jointly work on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases that affect many people worldwide, including age-related macular degeneration (AMD), diabetic macular edema (DME), geographic atrophy, Stargardt's disease, and retinal vein occlusion (RVO). The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases. Under the agreement, Bayer and the Wilmer Eye Institute of Johns Hopkins will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet medical need. Both parties will contribute personnel and infrastructure to address important scientific questions. Bayer will have an option for the exclusive use of the collaboration results. Financial terms of the agreement were not disclosed.

Similar Private Companies By Industry

Company Name Region
BioVeris Corporation United States
equinext, LLC United States
Linet Americas, Inc. United States
Polyzen Inc. United States
Axiom Technology Partners, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Bayer HealthCare LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at